AxoGen, Inc.
Financials
Valuation Metrics
AxoGen, Inc.'s Market Cap is $2.65B. At end of 2025 it was $1.54B. Ranked #1984 of 3,114 in US market (top 64%), #746 of 1,472 on NASDAQ (top 51%), #121 of 203 in Health Care Equipment & Services (top 60%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.65B | US#1,984/3,114 Sec#121/203 |
| Revenue | $267M | US#2,492/3,114 Sec#164/203 |
| Net Income | $-32M | US—/3,114 Sec—/203 |
| Total Assets | $550M | US#2,901/3,114 Sec#176/203 |
| Net Assets | $496M | US#2,576/3,114 Sec#151/203 |
| Employees | 622 | US#2,173/3,114 Sec#154/203 |
| Value | ||
| P/B | 5.34x | US#2,513/3,114 Sec#156/203 |
| P/S | 9.93x | US#2,595/3,114 Sec#170/203 |
| FCF Yield | 0.62% | US#2,245/3,114 Sec#140/203 |
| Profitability | ||
| ROE | -6.43% | US#2,404/3,114 Sec#139/203 |
| ROA | -5.80% | US#2,675/3,114 Sec#157/203 |
| Op. Margin | -5.17% | US#2,451/3,114 Sec#147/203 |
| Revenue Growth | 24.32% | US#572/3,114 Sec#35/203 |
| Financial Health | ||
| Debt Ratio | 10.93% | US#210/3,114 Sec#19/203 |
| Total Debt | $19M | US#2,749/3,114 Sec#173/203 |
| FCF | $16M | US#2,267/3,114 Sec#140/203 |
| Cash | $329M | US#2,261/3,114 Sec#141/203 |
| Current Ratio | 12.02x | US#369/3,114 Sec#25/203 |
| Performance | ||
| 1Y Return | 124.35% | US#112/3,114 Sec#20/203 |
| 1M Return | 33.32% | US#2,670/3,114 Sec#186/203 |
| From 52W High | -5.78% | US#1,922/3,114 Sec#149/203 |
| 1Y MDD | -33.08% | US#1,521/3,114 Sec#87/203 |
| Trading | ||
| Volume | 1,413,192 shares | US#717/3,114 Sec#30/203 |
| Trading Value | $70M | US#847/3,114 Sec#64/203 |
| Per Share | ||
| EPS | $-0.60 | US—/3,114 Sec—/203 |
| BPS | $9.33 | US#2,288/3,114 Sec#143/203 |
Company Info
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.